<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924465</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI036</org_study_id>
    <nct_id>NCT04924465</nct_id>
  </id_info>
  <brief_title>Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Autoantibodies Profile</brief_title>
  <acronym>TYPASS</acronym>
  <official_title>Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Antisynthetase Antibodies Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antisynthetase syndrome (ASS) is an overlap connective tissue disease characterized by the&#xD;
      presence of myositis-specific autoantibodies directed against tRNA-synthetases. Clinical&#xD;
      manifestations are myositis, interstitial lung disease (ILD), Raynaud's phenomenon,&#xD;
      mechanic's hands and polyarthritis. Clinical presentation varies between ASS patients. ASS is&#xD;
      potentially life threatening due to lung involvement, especially in rapidly progressive&#xD;
      forms. Anti-histidyl-tRNA synthetase (anti-Jo1) antibodies are the most frequently detected&#xD;
      antibodies in ASS (60 % of patients). Anti-threonyl-tRNA synthetase (anti-PL7) and&#xD;
      alanyl-tRNA synthetase (anti-PL12) antibodies are each detected in 10 % of patients&#xD;
      approximatively. Anti-tRNA-synthetases antibodies are mutually exclusive.&#xD;
&#xD;
      Clinical heterogeneity of ASS patients appears to be associated with specific autoantibodies&#xD;
      profile. Patients with anti-Jo1 antibodies have a more systemic presentation (especially with&#xD;
      muscle involvement), whereas patients with anti-PL7 or anti-PL12 antibodies have more&#xD;
      frequent and isolated ILD. If anti-PL7 and anti-PL12 antibodies are associated with more&#xD;
      severe ILD and poorer survival is still matter of debate.&#xD;
&#xD;
      Aims of this study were to compare ILD severity at diagnosis and clinical course in patients&#xD;
      with ASS according to antisynthetase autoantibodies types.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients of rapidly progressive (RP)- ILD</measure>
    <time_frame>3 months</time_frame>
    <description>Decrease of at least 10 percent of Forced Vital Capacity (FVC) OR Decrease of at least 5 % of FVC WITH Clinical worsening and/or ILD extension on CT-scan OR Decrease of at least 15 % of Diffusing Capacity of lung for Carbon Monoxide (DLCO) at 3 months of follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with severe ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Hypoxemia (PaO2 &lt; 60 mmHg) AND/OR Oxygen delivery at time of diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with ILD relapse</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>Clinical worsening AND/OR ILD extension on CT-scan AND/OR Progressive ILD on pulmonary function tests WITH modification of corticosteroids dosage or immunosuppressive drugs during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with chronic respiratory failure</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>Hypoxemia (PaO2 &lt; 70 mmHg) in a stable state during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients without death or lung transplant</measure>
    <time_frame>3 years and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Antisynthetase Syndrome</condition>
  <arm_group>
    <arm_group_label>Anti-Jo1</arm_group_label>
    <description>Patients with anti-Jo1 antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PL7</arm_group_label>
    <description>Patients with anti-PL7 antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PL12</arm_group_label>
    <description>Patients with anti-PL12 antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-EJ</arm_group_label>
    <description>Patients with anti-EJ antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-OJ</arm_group_label>
    <description>Patients with anti-OJ antibodies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up</intervention_name>
    <description>Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests</description>
    <arm_group_label>Anti-EJ</arm_group_label>
    <arm_group_label>Anti-Jo1</arm_group_label>
    <arm_group_label>Anti-OJ</arm_group_label>
    <arm_group_label>Anti-PL12</arm_group_label>
    <arm_group_label>Anti-PL7</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with antisynthetase syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with antisynthetase syndrome according to Connors criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul DECKER</last_name>
    <phone>+33383157240</phone>
    <email>p.decker@chru-nancy.fr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

